Anti-inflammatory Drugs

Card Set Information

Author:
sdespins
ID:
260940
Filename:
Anti-inflammatory Drugs
Updated:
2014-02-08 21:14:29
Tags:
Anti inflammatory Drugs
Folders:
Pharmacology
Description:
Anti-inflammatory Drugs
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user sdespins on FreezingBlue Flashcards. What would you like to do?


  1. A fully human IgG1 anti-TNF monoclonal antibody

    Binds to soluble TNF-a and prevent its interaction with TNF receptor

    Given subcutaneously; t1/2 = 10-20 days
    Adalimumab
  2. A recombinant, humanized antibody Fab fragment conjugated to a polyethylene glycol (PEG) with specificity to TNF-a

    Neutralizes membrane-bound and soluble TNF-a

    Given subcutaneously; t1/2 = 14 days
    Certolizumab
  3. A recombinant  fusion protein consisting of 2 soluble TNF p75 receptor moieties linked to the Fc portion of the human IgG1

    Binds to TNF-a and also inhibits lymphotoxin-a

    Given subcutaneously; t1/2 = 4.5 days
    Etanercept
  4. A human monoclonal antibody with a high affinity for soluble and membrane-bound TNF-a

    Given subcutaneously; t1/2 = 14 days
    Golimumab
  5. Infliximab
    A chimeric (25% mouse; 75% human) IgG1 monoclonal antibody with high affinity for soluble and possibly membrane-bound TNF-a

    Given via iv infusion; t1/2 = 9-12 days
  6. Side Effects of TNF inhibitors
    • Infections
    • Possibly risk of lymphoma 
    • Injection/infusion reactions
  7. -Umab suffix
    Human
  8. -omab suffix
    Mouse
  9. -ximab suffix
    Chimera
  10. -zumab suffix
    humanized
  11. -cept suffix
    Fusion protein
  12. A recombinant form of the endogenous IL-1 receptor antagonist (IL-1ra)

    Given subcutaneously, t1/2 = 4-6 hours
    Anakinra
  13. A recombinant human anti-IL-1b monoclonal antibody that binds to IL-1b and prevents it from binding to IL-1 receptor

    Given subcutaneously, t1/2 = 26 days
    Canakinumab
  14. A dimeric fusion protein consisting of the
    ligand-binding domains of the human IL-1 receptor 1 domain (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) fused to the Fc portion of human IgG1.

    Given subcutaneously
    Rilonacept
  15. Adverse effects of IL-1 inhibitors
    • Infections
    • Injection site reactions
  16. Humanized antibody that binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and inhibits
    IL-6-mediated signaling through these receptors

    t1/2: 11-23 days

    Indications:
    (1) given via iv or sc for rheumatoid arthritis; (2) given via iv for juvenile idiopathic arthritis (polyarticular or systemic)

    Adverse effects: infections; injection/infusion reactions
    Tocilizumab
  17. Human monoclonal antibody that binds to p40 subunit shared by IL-12 and IL-23 

    Given sc for treating plaque psoriasis and psoriatic arthritis

    Adverse effects: infections, injection site reactions
    Ustekinumab
  18. Fusion protein that complexes with costimulatory B7 molecules

    T cell anergy and apoptosis
    Abatacept
  19. Chimeric partially humanized anti-CD20 antibody

    B Cell Death inducing agent
    Rituximab
  20. Oral inhibitor of JAK pathway
    Tofacitinib

What would you like to do?

Home > Flashcards > Print Preview